Huntington's Disease Rilmenidine study
Huntington's Disease Rilmenindine Safety Trial
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
The proposed clinical drug trial is an open label safety study investigating a drug that has an action of autophagy in Huntington's Disease (HD). The medication being trialled is a drug that has been extensively used in humans previously for the treatment of hypertension. It has never been used before in HD however this drug has been shown to slow the disease down in animal models of HD. Given this and its good side effect profile and tolerability in people, it is a logical agent to try as a treatment in this currently incurable neurological condition.
East of England - Cambridge South Research Ethics Committee
Date of REC Opinion
23 Jul 2010
Further Information Favourable Opinion